newsfilter
← Latest News
GlobeNewswire·

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA